Weave Q2 Looks Solid-15.5% Growth and First Real Profit-But 92% Retention Still Tests the Bull Case

Weave Q2 made the profit story tangible

This quarter matters because Weave is doing more than growing: it is starting to convert that growth into profit and cash. After the usual software playbook of "growth first, profits later," Q2 showed 15.5% year-over-year revenue growth to $67.5 million in total revenue, operating income of $3.2 million, and a 4.7% operating margin that improved by 460 basis points year over year. Cash flow matched that progress, with $10.2 million of operating cash flow, $8.7 million of free cash flow, and $78.5 million in cash and short-term investments.

Why bulls see a better business model

The bull case is straightforward: Weave sells a useful tool to medical practices, is showing better sales discipline, and is generating cash rather than only growth. Payments revenue grew at roughly twice the rate of total revenue, which suggests the product is becoming more embedded in practice operations.

Why bears still have a case

The weak spot is retention. Weave still reported Dollar-Based Revenue Retention (NRR): 92% and Dollar-Based Revenue Retention (GRR): 89%. Those figures are not bad, but they fall short of the compounding customer-base profile that usually supports a rich software multiple. If retention improves, the cash-generation story can matter much more. If it stalls, investors may be left admiring a solid quarter rather than a clearly better business.

Product usage suggests Weave is becoming more embedded in workflow

The key question is no longer just whether Weave can post a good quarter. It is whether customers are using more of the product because it helps them run their practice. On balance, the signs point to yes.

Custom AI interactions are a useful signal

The clearest clue is custom AI interactions totaling $70 million, up 165% year over year. That points to hands-on use, not shelfware. Call Intelligence interactions also increased 143%. Together, those metrics suggest customers are engaging more with newer features, not merely staying subscribed at a distance.

The margin profile still looks software-like

Weave also reported a Subscription and Payment Processing Gross Margin: 77.9%. That is a strong figure for a software-adjacent platform and supports the idea that the core bundle has real product substance rather than sitting on just a thin layer of automation.

Efficiency improved alongside product traction

Expense discipline clearly helped. Sales and Marketing Expense: $25.8 million, or 38% of revenue, General and Administrative Expenses: $10 million, or 15% of revenue, and Research and Development Expenses: $10 million, or 15% of revenue still point to a lean cost structure. But usage is improving as well, payments are outgrowing total revenue, and the company reported Record gross and net location additions in Q2, with the largest increase in specialty medical. That makes the quarter look less like a one-off cost cut and more like a broader operating improvement.

Retention remains the real test of the bull case

What matters now is not whether Weave can post an isolated profitable quarter. After recent gains in Operating Income: $3.2 million and Cash from Operating Activities: $10.2 million in Q2, the metric that matters most is Dollar-Based Revenue Retention (NRR): 92%. For a company serving small and medium-sized healthcare businesses, that level still leaves little room for patience.

The easier task is staying cash-positive. The harder task-and the one most likely to reprice the stock-is pulling more customer dollars back into Weave over time. If net revenue retention moves toward or above 100%, investors can start to view Weave as a compounding business rather than just a decent operator. If it does not, the better profit story may not be enough.